MedTrace Logo

RAL-eve Study: Raltegravir Substitution Study

NCT00523237 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2011-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to:

* Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide,
* Monitor the safety and efficacy of raltegravir, and
* Assess the change in quality of life in patients who have switched from Enfuvirtide to raltegravir

Conditions

  • HIV Infections

Interventions

DRUG

Raltegravir

400 mg Twice daily for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Andrew R Zolopa · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523237 on ClinicalTrials.gov